Veloxis Pharmaceuticals can breathe easy as LCP-Tacro (tacrolimus), the sole product on which the company's hopes were based, has reported positive Phase III results in de novo kidney transplant patients, keeping the company on track for its planned US regulatory filing.
The News in a Nutshell
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?